CurrentBlue Cross Blue Shield - New MexicoPolicy MED207.154

Urine Drug Testing Documentation and Medical Necessity

Rules and documentation requirements for reimbursement of urine drug testing in pain management and substance use disorder monitoring for providers and laboratories submitting claims to BCBSNM.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyUrine Drug Testing Documentation and Medical Necessity

Policy CodePolicy MED207.154

Change TypeNo material change

Effective Date

Next Review Date

Key ActionDocument medical necessity for each quantitative urine drug test ordered and retain a signed requisition listing each specific drug or drug class tested.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4criteria that make quantitative testing medically necessary

9required data elements on requisition

3laboratory documentation date elements

1state submission rule

Coverage Criteria — When Testing Is Medically Necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medically necessary conditions: Qualitative testing was positive for a prescription drug that is not prescribed to the patient; OR qualitative testing was negative for a prescription drug that is prescribed to the patient; OR qualitative testing was positive for an illicit drug; OR a qualitative test for the relevant drug is not commercially available.

Medical necessity must be met for each drug or drug class for which a quantitative test is ordered.

inv-02: Not medically necessary

Quantitative testing is NOT medically necessary when ALL of the following are true:

Not medically necessary conditions: None of the four medical necessity criteria are met; AND the test is ordered as a routine screening or pursuant to standing/non-individualized orders.

Routine screenings and standing orders without individualized assessment are explicitly not medically necessary.

Tests performed as routine screening panels or pursuant to standing (non-individualized) orders are not considered medically necessary when they are done without a documented, individualized patient assessment. Routine screenings and standing orders lacking patient-specific clinical justification are explicitly not medically necessary.

Covered Indications

inv-13: Quantitative urine drug testing to confirm or measure a specific drug/class when medical necessity criteria are met

Quantitative (definitive) urine drug testing to confirm or measure a specific drug or drug class is covered when medical necessity criteria are documented for each drug/class tested.

Coverage requirement: A signed, written order from the ordering clinician documents the specific drug or drug class to be tested and medical necessity for quantitative testing is met per MED207.154.

The ordering clinician's written order must indicate each drug or drug class being tested; medical necessity must be met for each drug/class.

Laboratory documentation: Laboratory must retain a signed, valid requisition specifying the specific drugs or drug classes being tested, patient identity, ordering provider identity with credentials and NPI, legible physician signature, collection facility/location, sample type, date/time of collection, identity of collector, and date/time sample received by the laboratory.

If requisition or supporting documentation is insufficient to demonstrate medical necessity, additional records must be provided upon request.

Provider Actions and Documentation Requirements

Denial Risk

Triggers for Denial

BCBSNM requires documentation that supports medical necessity for each urine drug test ordered. Claims may be denied when documentation is incomplete, missing required elements, or insufficient to show medical necessity. The provider submitting the claim must furnish records upon request; laboratories should include a signed, valid requisition and full test results with each claim.

A claim may be denied if documentation does not demonstrate medical necessity for each drug or drug class tested (see MED207.154).
Claims can be denied when requisitions reference a non‑specific 'standard' or 'custom' panel rather than listing each specific drug or drug class.
Denial may occur if the requisition is unsigned, lacks the ordering provider's NPI, or omits patient identity, collection date/time, collection location, sample type, or the individual who collected the sample.
Laboratory claims can be denied if the lab cannot produce complete test results, CLIA identification, dates (collected/received/reported), or validity testing information.
Claims submitted to the wrong Blue Cross Blue Shield state plan (not the plan where the sample was obtained) may be denied.
Separate lab billing for services included in inpatient/intensive outpatient/residential treatment facility rates may be denied (do not unbundle).

Documentation Required

Medical necessity requirement — no explicit prior authorization

Quantitative/definitive testing must be documented as medically necessary per MED207.154. Documentation should describe the qualifying qualitative/presumptive result or the clinical rationale (for example: positive qualitative for an illicit drug; negative qualitative for a prescribed drug; qualitative positive for a non‑prescribed prescription drug; or lack of available qualitative test). Routine, standing, or non‑individualized orders without patient‑specific assessment are not medically necessary and may be denied.

Medical necessity must be shown for each drug/drug class tested.
Routine screenings or standing orders without individualized assessment are not covered.

Documentation Required

ORDERING REQUIREMENTS

The ordering provider must list each specific drug or drug class on the written order; reference to a 'standard panel' or 'custom panel' is not acceptable. The requisition must be signed (handwritten signature — no stamp or photocopy) and include the ordering provider's full name, credentials, and NPI.

Requisition must list each specific drug or drug class being tested (no generic panels).
Must include patient identity, ordering provider name/credentials/NPI, and a legible provider signature.
Include facility/location of collection, sample type, date/time collected, identity of collector, and date/time received by the laboratory.

Documentation Required

Required documentation elements

When laboratories submit claims, include in the requisition or supporting documentation: results and dates for relevant qualitative/screening tests, a list of the patient’s relevant prescribed medications, the laboratory’s complete identification (name, address, CLIA number), complete test results (including validity testing), and dates the sample was collected, received, and reported. If the laboratory’s records are insufficient, BCBSNM will request additional documentation; failure to provide it can lead to claim denial or appeal loss.

Include qualitative point‑of‑care/screening test details (date, drugs/classes tested, results).
Provide a list of prescribed medications relevant to the tests ordered.
Laboratory documentation must show lab identification (including CLIA), patient name/DOB, ordering provider name and NPI, facility name (if applicable), collection/received/report dates, and complete results.

Ordering Requirements

Note

Ordering clinician must submit a signed, specific requisition

The ordering clinician must provide a signed, valid written requisition that names each specific drug or drug class being tested and includes full ordering-provider identification and collection details.

Requisition must list specific drugs/drug classes (not a 'custom panel')
Include ordering provider name, credentials, NPI, and legible signature
Include patient identity, collection location, sample type, collection date/time, collector identity, and date/time received by laboratory

Not Covered Services

NOT COVERED: Routine screening panels and tests ordered pursuant to standing/non-individualized orders without documentation of individualized patient assessment are not medically necessary and are not covered. Also not covered are laboratory services that are included in facility rates for inpatient, intensive outpatient, or residential behavioral health settings when those services are unbundled and billed separately.

Definitions

Qualitative testing — definition of presumptive testing

DefinitionQualitative (presumptive) testing is a screening test that provides a positive or negative result for a drug or drug class (used as the initial, point-of-care or screening step).

Role in workflowServes as the initial presumptive screen whose results determine whether follow-up quantitative (definitive) testing may be medically necessary for a given drug or drug class.

Relation to medical necessityQuantitative testing may be needed when qualitative results are discordant with prescribed medications or indicate illicit use (see quantitative criteria).

LimitationsDoes not measure drug concentration; may not distinguish specific drugs within a class and therefore often requires confirmatory testing for definitive identification or quantification.

Quantitative (definitive) testing — definition and relation to medical necessity criteria

DefinitionQuantitative (definitive) testing is performed to confirm and/or measure the level of a specific drug or drug class (provides definitive identification and concentration).

Medical necessity criteria (any one qualifies)Medically necessary when: qualitative testing is positive for a prescription drug not prescribed to the patient; OR qualitative testing is negative for a prescription drug that is prescribed to the patient; OR qualitative testing is positive for an illicit drug; OR a qualitative test for the relevant drug is not commercially available.

Requirement per drug/classMedical necessity must be documented for each drug or drug class for which quantitative testing is ordered.

Not medically necessary scenariosQuantitative testing is not medically necessary when none of the four criteria are met, including when testing is ordered as routine screening or pursuant to standing/non-individualized orders.

Background

Quantitative (definitive) urine drug testing is used to confirm or measure specific drugs or drug classes following a presumptive or qualitative screen, or when a qualitative test is not available. Qualitative (presumptive) testing provides an initial positive/negative result for specified drugs or classes, while quantitative testing confirms the presence of a drug and reports a measured level, which may be required to determine medical necessity when the qualitative result is discordant with prescribed medications or indicates illicit drug use.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyUrine Drug Testing Documentation and Medical Necessity

Policy CodePolicy MED207.154

Change TypeNo material change

Effective Date

Next Review Date

Key ActionDocument medical necessity for each quantitative urine drug test ordered and retain a signed requisition listing each specific drug or drug class tested.

SourceLink

On This Page